Thornburg Investment Management Inc. Purchases 48,763 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Thornburg Investment Management Inc. raised its position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 232.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 69,751 shares of the company's stock after acquiring an additional 48,763 shares during the quarter. Thornburg Investment Management Inc.'s holdings in Dr. Reddy's Laboratories were worth $1,101,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of RDY. Robeco Institutional Asset Management B.V. boosted its position in shares of Dr. Reddy's Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock worth $180,620,000 after purchasing an additional 9,373,412 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Dr. Reddy's Laboratories by 403.1% during the 4th quarter. Royal Bank of Canada now owns 10,037,246 shares of the company's stock worth $158,489,000 after purchasing an additional 8,042,163 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Dr. Reddy's Laboratories by 382.9% during the 4th quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company's stock worth $148,717,000 after purchasing an additional 7,467,979 shares in the last quarter. Aikya Investment Management Ltd boosted its position in shares of Dr. Reddy's Laboratories by 416.1% during the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock worth $88,590,000 after purchasing an additional 4,523,303 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Dr. Reddy's Laboratories by 405.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 5,361,013 shares of the company's stock worth $84,643,000 after purchasing an additional 4,301,212 shares in the last quarter. Institutional investors own 3.85% of the company's stock.

Dr. Reddy's Laboratories Trading Up 0.3%

RDY opened at $14.44 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. Dr. Reddy's Laboratories Limited has a fifty-two week low of $12.26 and a fifty-two week high of $16.89. The firm has a market capitalization of $12.05 billion, a PE ratio of 22.99 and a beta of 0.33. The company's 50-day moving average is $13.43 and its 200 day moving average is $14.03.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.02. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The company had revenue of $996.17 million for the quarter, compared to analyst estimates of $83.70 billion. As a group, research analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.